Antitubercular Agents | UTIs | Antiviral Agents | Unit 3 Medicinal Chemistry 6th Semester

The lecture begins with an extensive discussion of antitubercular agents, explaining tuberculosis as a chronic infectious disease caused by Mycobacterium tuberculosis. The instructor describes how TB can be classified based on site of action (pulmonary vs extrapulmonary) and active state (active vs latent TB). He emphasizes the critical importance of patient compliance with treatment, explaining how first-line drugs (Isoniazid, Rifampin, Pyrazinamide, and Ethambutol) work as a four-drug combination therapy for 9-12 months, and how non-compliance can lead to multi-drug resistant TB requiring second-line drugs. The lecture covers detailed mechanisms of action for synthetic antitubercular drugs and antitubercular antibiotics, including synthesis pathways for key drugs like Isoniazid and para-aminosalicylic acid.

The second major section covers urinary tract infections and their treatment agents. The instructor explains UTIs as bacterial infections affecting any part of the urinary system (kidneys, ureters, bladder, urethra), with E. coli being the most common causative organism. He discusses four types of UTIs: cystitis, urethritis, pyelonephritis, and ureteritis, along with their symptoms. The treatment focuses on quinolones, particularly explaining their mechanism through DNA replication interference by blocking topoisomerase enzymes. A detailed structure-activity relationship analysis of quinolones is provided, followed by synthesis of ciprofloxacin and discussion of miscellaneous drugs like nitrofurantoin.

The final section addresses antiviral agents, distinguishing between antiretroviral agents (targeting retroviruses like HIV that convert RNA to DNA via reverse transcription) and non-retroviral agents (targeting other viruses). For antiretrovirals, he covers NRTIs (nucleoside reverse transcriptase inhibitors), NNRTIs (non-nucleoside reverse transcriptase inhibitors), and protease inhibitors, explaining their mechanisms in disrupting HIV replication. Non-retroviral agents include anti-herpes drugs like acyclovir, anti-influenza drugs that prevent viral uncoating, and anti-hepatitis C drugs like ribavirin that work through multiple mechanisms including viral RNA polymerase interference and lethal mutagenesis.